Formulation and characterization of bufadienolides-loaded nanostructured lipid carriers

References

• Krenn L, Kopp B. (1998). Bufadienolides from animal and plant sources. Photochemistry, 48:1–29.
   Web of Science ®Google Scholar
• Steyn PS, Van Heerden FR. (1998). Bufadienolides of plant and animal origin. Nat Prod Rep, 15:397–413.
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Jing Y, Kawazoe N, Masuda Y, Nakajo S, Yoshida T, . (1997). Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs. Leuk Res, 21:875–83.
   PubMed Web of Science ®Google Scholar
• Kamano Y, Yamashita A, Nogawa T, Morita H, Takeya K, Itokawa H, . (2002). QSAR evaluation of the Chan Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/51. J Med Chem, 45:5440–7.
   PubMed Web of Science ®Google Scholar
• Yeh JY, Huang WJ, Kan SF, Wang PS. (2003). Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate, 54:112–24.
   PubMed Web of Science ®Google Scholar
• Chen KK, Kovarikove A. (1967). Pharmacology and toxicology of toad venom. J Pharm Sci, 56:1535–41.
   PubMed Web of Science ®Google Scholar
• Li F, Yang R, Weng Y, Tang X. (2009). Preparation and evaluation of lyophilized liposome-encapsulated bufadienolides. Drug Dev Ind Pharm, 35:1048–58.
   PubMed Web of Science ®Google Scholar
• Müller RH, Petersen RD, Hommoss A, Pardeike J. (2007). Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev, 59:522–30.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 54:131–55.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. (2002). Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm, 242:121–8.
   PubMed Web of Science ®Google Scholar
• Garcia-Fuentes M, Aolores MJ, Torres D. (2005). Design and characterization of a new drug nanocarrier made from solid–liquid lipid mixtures. J Colloid Interface Sci, 285(2):590–8.
   PubMed Web of Science ®Google Scholar
• Joshi MD, Müller RH. (2009). Lipid nanoparticles for parenteral delivery of actives. Adv Drug Deliv Rev, 71(2):161–72.
   Google Scholar
• Joshi M, Patravale V. (2006). Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of valdecoxib. Drug Dev Ind Pharm, 32:911–8.
   PubMed Web of Science ®Google Scholar
• Müller RH, Rühl D, Runge S, Schulze-Forster K, Mehnert W. (1997). Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res, 14:458–62.
   PubMed Web of Science ®Google Scholar
• Hu LD, Tang X, Cui FD. (2004). Solid–lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol, 56:1527–35.
   PubMed Web of Science ®Google Scholar
• Müller RH, Schmidt S, Buttle I, Akkar A, Schmitt J, Brömer S. (2004). Solemuls-novel technology for the formulation of i.v. emulsion with poorly soluble drugs. Int J Pharm, 269:293–302.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang Y, Tang X, Zhang HY. (2009). Determination of entrapment efficiency and drug phase distribution of submicron emulsions loaded silybin. J Microencapsul, 26:180–6.
   PubMed Web of Science ®Google Scholar
• Joshi M, Patravale V. (2008). Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm, 346:124–32.
   PubMed Web of Science ®Google Scholar
• Yuan H, Wang LL, Du YZ, You J, Hu FQ, Zeng S. (2007). Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B Biointerfaces, 60:174–9.
   PubMed Web of Science ®Google Scholar
• Zhang XX, Pan WS, Gan L, Zhu CL, Gan Y, Nie SF. (2008). Preparation of a Dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem Pharm Bull, 56:1645–50.
   PubMed Web of Science ®Google Scholar
• Liu K, Sun J, Wang Y, He Y, Gao K, He ZG. (2008). Preparation and characterization of 10-hydroxycamptothecin loaded nanostructured lipid carriers. Drug Dev Ind Pharm, 34:465–71.
   PubMed Web of Science ®Google Scholar
• Lim SJ, Kim CK. (2002). Formulation parameters determining the physicochemical characteristics of solid–lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm, 243:135–46.
   PubMed Web of Science ®Google Scholar
• Müller RH, Rühl D, Runge SA. (1996). Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm, 144:115–21.
   Web of Science ®Google Scholar
• Zimmermann E, Müller RH. (2001). Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticle (SLN™) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm, 52:203–10.
   PubMed Web of Science ®Google Scholar
• Plock N, Kloft C. (2005). Microdialysis—theoretical background and recent implementation in applied life-sciences. Eur J Pharm Sci, 25:1–24.
   PubMed Web of Science ®Google Scholar
• Jenning V, Thünemann AF, Gohla SH. (2000). Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm, 199:167–77.
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser O, Müller RH. (2004). Solid–lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 56:1257–72.
   PubMed Web of Science ®Google Scholar
• Hu FQ, Jiang SP, Du YZ. (2005). Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces, 45:167–73.
   PubMed Web of Science ®Google Scholar
• zur Mühlen A, zur Mühlen E, Niehus H, Mehnert W. (1996). Atomic force microscopy studies of solid lipid nanoparticles. Pharm Res, 13:1411–6.
   PubMed Web of Science ®Google Scholar